The impact of entecavir on T lymphocytes PD-1 levels in peripheral blood and liver function of CHB patients

Objective To investigate the impact of entecavir on the levels of peripheral blood T lymphocytes programmed death receptor 1( PD-1) and liver function of patients with chronic hepatitis B( CHB). Methods 128 CHB patients were randomly divided into observation group( n = 64) and control group( n = 64). The control group were treated with lamivudine therapy. The observed group were given entecavir on the basis of the therapy given to control group. The levels of T lymphocytes PD-1 expression in the two groups were detected with flow cytometry,the levels of HBV DNA were detected with quantitative PCR,and the levels of ALT were detected with fully automated biochemical before treatment and one month,three months,six months and 12 months after treatment. Results The levels of HBV DNA load,ALT,CD4+T cells in PD-1,and CD8+T cells in PD-1 in the two groups after treatment were lower than before treatment( P 0. 05). The levels of HBV DNA load,ALT,CD4+T cells in PD-1 and CD8+T cells in PD-1 in observation group at one month,three months,six months and 12 months after treatment were lower than those in the control group( P 0. 05). Conclusion Entecavir can effectively inhibit the CD4+and CD8+T cell surface PD-1 expression levels,thereby inhibiting HBV DNA replication and improve liver function.